These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35912984)

  • 21. Role of diffusion tensor imaging or magnetic resonance spectroscopy in the diagnosis and disability assessment of amyotrophic lateral sclerosis.
    Liu C; Jiang R; Yi X; Zhu W; Bu B
    J Neurol Sci; 2015 Jan; 348(1-2):206-10. PubMed ID: 25524526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How COVID-19 pandemic changed our management strategies for amyotrophic lateral sclerosis (ALS) patients: Egyptian study.
    Rashed HR
    Egypt J Neurol Psychiatr Neurosurg; 2021; 57(1):80. PubMed ID: 34629844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.
    Tramacere I; Dalla Bella E; Chiò A; Mora G; Filippini G; Lauria G;
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1180-5. PubMed ID: 25886781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers.
    Manera U; Solero L; Fournier CN; Canosa A; Vasta R; Bombaci A; Grassano M; Palumbo F; Torrieri MC; Salamone P; Casale F; Fuda G; Moglia C; Calvo A; Chiò A
    Amyotroph Lateral Scler Frontotemporal Degener; 2022 Aug; 23(5-6):424-429. PubMed ID: 34894916
    [No Abstract]   [Full Text] [Related]  

  • 25. Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database.
    Bacci ED; Staniewska D; Coyne KS; Boyer S; White LA; Zach N; Cedarbaum JM;
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(3-4):157-67. PubMed ID: 26473473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurochemical correlates of functional decline in amyotrophic lateral sclerosis.
    Cheong I; Deelchand DK; Eberly LE; Marjańska M; Manousakis G; Guliani G; Walk D; Öz G
    J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):294-301. PubMed ID: 30467209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach.
    Thakore NJ; Lapin BR; Kinzy TG; Pioro EP
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):483-494. PubMed ID: 30001159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).
    Cedarbaum JM; Stambler N; Malta E; Fuller C; Hilt D; Thurmond B; Nakanishi A
    J Neurol Sci; 1999 Oct; 169(1-2):13-21. PubMed ID: 10540002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.
    Bakers JNE; de Jongh AD; Bunte TM; Kendall L; Han SS; Epstein N; Lavrov A; Beelen A; Visser-Meily JMA; van den Berg LH; van Eijk RPA
    Amyotroph Lateral Scler Frontotemporal Degener; 2022 Nov; 23(7-8):500-507. PubMed ID: 34949141
    [No Abstract]   [Full Text] [Related]  

  • 30. Utility of the ALSFRS-R for predicting ALS and comorbid disease neuropathology: The Veterans Affairs Biorepository Brain Bank.
    Colvin LE; Foster ZW; Stein TD; Thakore-James M; Salajegheh MK; Carr K; Spencer KR; Abdul Rauf N; Adams L; Averill JG; Walker SE; Robey I; Alvarez VE; Huber BR; McKee AC; Kowall NW; Brady CB
    Muscle Nerve; 2022 Aug; 66(2):167-174. PubMed ID: 35585776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].
    Liu XX; Fan DS; Zhang J; Zhang S; Zheng JY
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2472-5. PubMed ID: 20137433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and results of a smartphone-based digital phenotyping study to quantify ALS progression.
    Berry JD; Paganoni S; Carlson K; Burke K; Weber H; Staples P; Salinas J; Chan J; Green JR; Connaghan K; Barback J; Onnela JP
    Ann Clin Transl Neurol; 2019 May; 6(5):873-881. PubMed ID: 31139685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
    Shefner JM; Jacobsen B; Kupfer S; Malik FI; Meng L; Wei J; Wolff AA; Rudnicki SA
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):162-169. PubMed ID: 37641579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients.
    Pirola A; De Mattia E; Lizio A; Sannicolò G; Carraro E; Rao F; Sansone V; Lunetta C
    Clin Neurol Neurosurg; 2019 Sep; 184():105456. PubMed ID: 31382080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice.
    Ludolph AC; Corcia P; Desnuelle C; Heiman-Patterson T; Mora JS; Mansfield CD; Couratier P
    Muscle Nerve; 2024 Jul; 70(1):36-41. PubMed ID: 38712849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale in Poland and its reliability in conditions of the medical experiment.
    Maksymowicz S; Kukołowicz P; Siwek T; Rakowska A
    Neurol Sci; 2021 Mar; 42(3):943-949. PubMed ID: 32676760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale.
    Balendra R; Jones A; Jivraj N; Knights C; Ellis CM; Burman R; Turner MR; Leigh PN; Shaw CE; Al-Chalabi A
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Jun; 15(3-4):279-84. PubMed ID: 24720420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis.
    Rooney J; Burke T; Vajda A; Heverin M; Hardiman O
    J Neurol Neurosurg Psychiatry; 2017 May; 88(5):381-385. PubMed ID: 27888187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R.
    Bakker LA; Schröder CD; Tan HHG; Vugts SMAG; van Eijk RPA; van Es MA; Visser-Meily JMA; van den Berg LH
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):75-81. PubMed ID: 31558653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis.
    Hu N; Shen D; Yang X; Cui L; Liu M
    J Clin Neurosci; 2022 Mar; 97():93-98. PubMed ID: 35074582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.